The basis for referral was that there were divergences in the Summaries of Product Characteristics (SPC) of Neurontin (and associated names) approved across EU Member States, Iceland and Norway, in particular with respect to indications, posology, contra-indications, undesirable effects and sections dealing with the recommendations for use due to divergent national decisions.